The U.S. Food and Drug Administration rejected ImClone 's original a application in December 2001 , saying the a trial had been sloppily conducted .
The Food and Drug Administration ultimately denied ImClone 's a drug a application in December 2001 , saying that an Erbitux clinical a trial was deficient .